Researchers of the Orthopaedic Research Laboratory of the Radboudumc, together with the LUMC, received a grant of €180k from the Innovatiefonds Zorgverzekeraars for clinical implementation of patient-specific computer models for fracture risk prediction in patients with bone metastases.Patients with cancer can suffer from bone metastases in the femur. These bone metastases are usually very painful and increase the risk of a fracture. Treatment of bone metastases is based on the fracture risk: patients with a low fracture risk will be treated with radiotherapy for pain management, whereas patients with a high fracture risk are considered for preventive surgery. According to current clinical guidelines, fracture risk is assessed by measuring the size of the metastases on X-rays or CT scans. However, it appears that using this method, there are patients who receive unnecessary preventive surgery, as well as patients who fracture their femur although they were assessed as low risk.
The research team of the Radboudumc, consisting of Nico Verdonschot, Esther Tanck and PhD candidate Florieke Eggermont, and Yvette van der Linden of the LUMC, developed a patient-specific computer simulation that can predict fracture risk in patients with bone metastases. This computer simulation calculates bone strength based on a CT scan, and appears to be better at estimating fracture risk in comparison to the clinical guidelines. Therefore, they received a grant of €180k from the Innovatiefonds Zorgverzekeraars to initiate clinical implementation of the computer model. The idea is that clinicians can order a computer simulation at the Orthopaedic Research Lab if they are unsure about the patient’s fracture risk. They will then receive a patient-specific fracture risk prediction based on the calculations, which can be used in the consultation with the patient to determine the best treatment option.
Florieke Eggermont, Esther Tanck and Nico Verdonschot are members of theme Reconstructive and regenerative medicine.
Related news items
Radboud Young Academy safeguards the future of science21 January 2021
New platform to provide advice on policy, create an interdisciplinary network of early career scientists, and promote career development.read more
Increase radio- and immunotherapy efficacy by targeting hypoxia21 January 2021
In a paper recently accepted by Clinical Cancer Research, Daan Boreel, together with Paul Span, Sandra Heskamp, Gosse Adema and Jan Bussink, reviews the therapeutic potential of decreasing the lack of oxygen (hypoxia) often found in solid tumors.read more
Radiation boost lowers risk of prostate cancer recurrence21 January 2021
An additional external-beam radiation dose delivered directly to the tumor can benefit the prospects of men with non-metastatic prostate cancer, without causing additional side effects. The risk of relapse within five years for these men is smaller than for men who did not receive this boost.read more
New research through grants for Radboudumc researchers14 January 2021
Several researchers at the Radboudumc have received grants to start new studies, including on rare diseases, liver disease and cancer metastases. These are grants from the Dutch Research Council, European Joint Programme on Rare Diseases and the Gastric Liver Disease Foundation.read more
Should we prepare for a corona-related depression wave? Indira Tendolkar and Eric Ruhé talk about their research projects13 January 2021
Since the outbreak of the SARS-CoV-2, many of us have been staying at home in order to limit our social interactions, to keep ourselves and others safe from the virus. Yet, there’s also concern about what social distancing and anxiety generated by media reports are doing to people's mental health.read more
RIMLS online award ceremony proudly presenting the winners13 January 2021
In this special webinar of the RIMLS New Year Celebration, scientific director René Bindels reviewed 2020 and looked forward to 2021. But more importantly a number of researchers received prizes in the traditional RIMLS awards ceremony.read more